Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.

Abstract

AIMS:

22q11.2 deletion syndrome (22q11.2DS) is associated with impaired cognitive functioning. Glutamatergic pathways have been linked with cognition and are hypothesized to be disrupted in 22q11.2DS patients, possibly 'shifting' the excitatory (glutamate)/inhibitory (GABA) balance. Hence, the glutamate/GABA balance may constitute a target for pharmacological treatment. We aimed to examine alterations of glutamate/GABA metabolites in 22q11.2DS in vivo using riluzole, a compound with glutamate/GABA-modulating action, as pharmacological challenge.

METHODS:

Seventeen 22q11.2DS patients and 20 matched healthy controls were enrolled in this randomized double-blind placebo-controlled crossover study. Glutamate and glutamine concentrations in the anterior cingulate cortex (ACC) and striatum, as well as ACC GABA concentrations were obtained after placebo and after a single dose of 50 mg riluzole using 7-Tesla magnetic resonance spectroscopy (MRS). Within the 22q11.2DS group, the relationship between metabolite concentrations and cognition was examined.

RESULTS:

No group differences were found in ACC and striatal metabolite concentrations following placebo. Riluzole numerically decreased ACC (η2= 0.094) but not striatal glutamate concentrations as well as ACC GABA concentrations (η2= 0.176) in all subjects. In both regions, riluzole did not alter glutamine concentration. No interaction effects were found. Although not significant after Bonferroni correction, ACC glutamate concentrations were inversely correlated with cognitive functions in 22q11.2DS patients.

DISCUSSION:

We did not demonstrate altered ACC and striatal metabolite concentrations in 22q11.2DS. Nevertheless, these results suggest that glutamate and GABA can be modulated with a single dose of riluzole. Possibly, riluzole may have memory-enhancing effects in 22q11.2DS. Future studies should examine the long-term effects of riluzole on cognition.

• Authors: Claudia Vingerhoets, Desmond Hy Tse, Mathilde van Oudenaren, Dennis Hernaus, Esther van Duin, Janneke Zinkstok, Johannes G Ramaekers, Jacobus Fa Jansen, Grainne McAlonan, Therese van Amelsvoort
• Journal: Journal of psychopharmacology (Oxford, England) (J Psychopharmacol) Vol. 34 Issue 8 Pg. 856-863 (08 2020) ISSN: 1461-7285 [Electronic] United States
• PMID: 32448020 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Excitatory Amino Acid Antagonists
• Glutamic Acid
• gamma-Aminobutyric Acid
• Riluzole

Topics

• Adult
• Attention (physiology)
• Cognition (physiology)
• Corpus Striatum (diagnostic imaging, drug effects, metabolism)
• Cross-Over Studies
• DiGeorge Syndrome (diagnostic imaging, metabolism)
• Double-Blind Method
• Excitatory Amino Acid Antagonists (administration & dosage, pharmacology)
• Female
• Glutamic Acid (metabolism)
• Gyrus Cinguli (diagnostic imaging, drug effects, metabolism)
• Humans
• Magnetic Resonance Spectroscopy
• Male
• Memory (physiology)
• Riluzole (administration & dosage, pharmacology)
• Young Adult
• gamma-Aminobutyric Acid (metabolism)